Key Takeaways:
- CMS shelved the planned BALANCE model indefinitely in April 2026 after major insurers declined to participate
- Medicare GLP-1 Bridge extended through December 31, 2027, maintaining $50 monthly copays for eligible seniors
- Congressional action would be required to make obesity drug coverage permanent in Medicare
- The Bridge program now serves as the only Medicare pathway for GLP-1 medications like Wegovy and Zepbound
CMS Pulls the Plug on Long-Term Medicare GLP-1 Plan
On April 21, 2026—the day after applications closed for Medicare Part D plans to join the BALANCE model—CMS announced it would not move forward with the program in 2027. The agency cited the need for "further evaluation and data collection" after major Part D plan sponsors proved reluctant or unwilling to participate.
The Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model was supposed to be the permanent solution for Medicare GLP-1 coverage. Originally scheduled to begin in January 2027 and end in December 2031, the program would have allowed Part D plans to voluntarily offer GLP-1 medications for weight loss with government-negotiated pricing.
While CMS sought robust participation from Part D plan sponsors, interest fell short of targeted levels. Although GLP-1 manufacturers agreed to a $245 net price—a substantial discount from prevailing list prices—savings from lower prices may not have offset higher costs associated with increased GLP-1 use for obesity treatment.
Why Insurers Said No to BALANCE
According to Abe Sutton, director of the Center for Medicare and Medicaid Innovation, plans were concerned about instability in Part D and felt they lacked the full picture of utilization under the model. The financial risks were significant for insurers.
Plans would have been at financial risk if their actual costs for covering GLP-1s were higher than expected. Higher costs for Part D plans under the BALANCE model would have translated to higher federal spending and increased Part D premiums for enrollees.
The model was discussed on UnitedHealth Group's earnings call, with Bobby Hunter, CEO of government programs, saying there were still industry concerns that hadn't been addressed: "We'd like to find a path to yes there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure."
Bridge Program Becomes the Only Option
The Medicare GLP-1 Bridge program now stands as the only pathway to access for seniors seeking obesity treatment, after the longer-term BALANCE model was shelved indefinitely. The Bridge, originally designed as a 6-month stopgap, was quietly extended through December 31, 2027.
Under the Bridge program, eligible individuals enrolled in Medicare Part D prescription drug plans can access GLP-1 medications at a predictable $50 for a monthly supply. Eligible medications include all formulations of semaglutide injection (Wegovy), tirzepatide (Zepbound), and other approved GLP-1 formulations for obesity treatment.
The Bridge operates entirely outside the standard Part D benefit, with Humana serving as the central processor managing prior authorization, claims adjudication, and pharmacy reimbursement. Drug manufacturers have agreed to a negotiated net price of $245 per 30-day supply.
The Cost Reality Behind the Delay
The cost to Medicare of covering obesity drugs under Part D has been estimated at between $25 billion and $50 billion over 10 years. The popularity of these GLP-1 medications is estimated to cost $35 billion from 2026 to 2034, according to recent analyses.
These massive cost projections help explain why insurers were hesitant to commit. Unlike the Bridge program—where the government bears all financial risk—BALANCE would have put Part D plans on the hook for utilization that could far exceed projections.
The financial uncertainty extends beyond Medicare. For those researching their options, understanding GLP-1 cost considerations becomes crucial, especially as coverage landscapes continue shifting rapidly.
What This Means for You
If you're approaching 65 or currently on Medicare, this development fundamentally changes your GLP-1 access timeline. GLP-1 loss at Medicare eligibility had become a defining fear for many approaching age 65, with patients often terrified to lose employer-sponsored insurance coverage and access to Wegovy and Zepbound.
The Bridge program provides temporary relief, but the critical question remains: Will they continue this after December 2027, or will you get short-term benefit that isn't sustainable long-term? This sort of temporary coverage that gets pulled back wouldn't happen for other medical conditions.
Your Next Steps:
- If you're currently on a GLP-1 and approaching Medicare eligibility, document your treatment history and outcomes
- Research which Part D plans in your area will honor the Bridge program requirements
- Consider discussing backup treatment options with your healthcare provider
The uncertainty means having a plan becomes even more important. If you need help navigating your GLP-1 options as Medicare eligibility approaches, find a clinic near you that specializes in weight management transitions. Many providers are developing strategies to help you maintain access during these uncertain times, including alternative medications and bridging protocols.
The Congressional Wild Card
Congressional action would be required to make obesity drug coverage permanent in Medicare. With the BALANCE model indefinitely shelved, legislative intervention may be the only path to long-term, stable Medicare coverage for GLP-1 medications.
However, the $25-50 billion price tag over 10 years makes Congressional approval far from certain. Lawmakers will need to weigh the long-term health benefits and potential cost savings against immediate budget impacts.
For now, the Bridge program serves as your lifeline—but with a clear expiration date that leaves many questions unanswered about what comes next.
Sources
- CMS Announces Changes to Medicare Coverage of GLP-1 Medications for 2027 - Obesity Medicine Association report on BALANCE model delay
- What to Know About the BALANCE Model for GLP-1s - KFF analysis of Medicare GLP-1 coverage changes
- CMS delays Part D GLP-1 model amid skepticism from insurers - Industry report on insurer concerns
- What You Need To Know Before the Medicare GLP-1 Bridge Goes Live - Clinical analysis of Bridge program implications